Deployment

Pixel Watch (made by Google, part of Alphabet; current model the Pixel Watch 4 from October 9, 2025) is a biometric-primary smartwatch with cardiac AI augmentation, recorded in the new biometric form factor under a new Google company entity, with its health stack running on Fitbit and Google Health algorithms since Google owns Fitbit. Its standout FDA clearance is Loss of Pulse Detection, cleared on February 26, 2025 as the first feature of its kind, which detects a loss-of-pulse event such as cardiac arrest, respiratory or circulatory failure, or overdose and automatically prompts a call to emergency services if the user is unresponsive, alongside the Fitbit-lineage ECG app cleared in 2020 and atrial-fibrillation notifications cleared in 2022 carried into the Pixel Watch. A cap-flag applies because Loss of Pulse Detection is not a cardiac-monitoring or diagnostic feature and is explicitly excluded for users with preexisting heart conditions or those needing cardiac monitoring, with Google noting it may not detect every instance, so marketing it as general heart safety for cardiac patients exceeds the indication, and the cited 98.7-percent sensitivity and 100-percent specificity ECG figures are Google-reported algorithm performance. Fitbit, also Google-owned through its 2021 acquisition, is recorded as a separate registry entity, and the Fitbit app was rebranded to Google Health on May 7, 2026 with an optional $9.99-per-month premium tier gating a Gemini-powered AI coach. Its clinical-validation posture is growing, anchored by the large Fitbit Heart Study and Google's own loss-of-pulse validation but with lower independent peer-review volume than Apple, and the exact loss-of-pulse FDA submission number and whether the Pixel Watch 4 adds net-new clearances beyond inherited features are not verified.

Pixel Watch by Google · Catalog entry · 1 source · not yet field-verified